Omega-3 fatty acids' supplementation in Parkinson's disease: A systematic review of randomized controlled trials
Abstract
Summary: Parkinson's disease (PD) is a neurodegenerative disorder, in which loss of dopaminergic neurons is present among other alterations. Lipids are key molecules in PD pathophysiology. Patients with PD may have lower levels of circulating omega-3 fatty acids, which are vital components of the brain cells' membranes, exerting anti-inflammatory properties and affecting neural function. The present systematic review of randomized controlled trials (RCTs) assessed the potential beneficial effects of omega-3 fatty acids' supplementation in patients with PD. Several accurate databases were used, including PubMed, Cochrane, and Scopus, as well as grey literature sources. Four RCTs were finally identified, in which different doses of omega-3 fatty acids were administered together with vitamin E. Three RCTs investigated the effects of omega-3 fatty acids on the progression of PD with the use of Unified Parkinson's Disease Rating Stage (UPDRS) score, and all showed beneficial effects. Moreover, some beneficial effects were reported for depression scales, as well as against insulin resistance, markers of inflammation, and oxidative stress. However, further studies are highly recommended to substantiate the role of omega-3 fatty acids' supplementation in the clinical course of PD.
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Promising Sources of Plant-Derived Polyunsaturated Fatty Acids: A Narrative Review
- Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: Systematic review and meta-analysis of randomized controlled trials
- Effect of omega-3 fatty acids on cognition: an updated systematic review of randomized clinical trials
- The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus: A narrative review
- Paucity of evidence for a relationship between long-chain omega-3 fatty acid intake and chronic obstructive pulmonary disease: a systematic review
- Omega-3 fatty acid nanocarriers: Characterization and potential applications
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.